SPHS Sophiris Bio

Sophiris Bio Inc. is a late-stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin has completed two Phase 2 clinical trials for the focal treatment of localized prostate cancer and has completed one Phase 3 study of topsalysin for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Topsalysin is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells. For more information, please visit

Company profile

SPHS stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


8 Nov 19
15 Oct 21
31 Dec 21

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

0.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2 2
Opened positions 0 1 EXIT
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 10.49K 10.49K
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Meeder Asset Management 10K $0 0.0%
IFP Advisors 490 $0 0.0%
Largest transactions
Shares Bought/sold Change
Meeder Asset Management 10K 0 0.0%
IFP Advisors 490 0 0.0%

Financial report summary

Content analysis
H.S. junior Avg
New words: AgreementSM, ATM, binding, EPS, exploring, fundamental, nonsubstantive, post, preceding, redeemed, supplement, Supplemental
Removed: consume, conversion, faster, therapeutic, thereon, uncertainty